Sivia Capital Partners LLC Buys 889 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Sivia Capital Partners LLC lifted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 16.7% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 6,227 shares of the company’s stock after buying an additional 889 shares during the quarter. Sivia Capital Partners LLC’s holdings in Dr. Reddy’s Laboratories were worth $474,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of RDY. QRG Capital Management Inc. lifted its position in Dr. Reddy’s Laboratories by 2.3% during the second quarter. QRG Capital Management Inc. now owns 7,910 shares of the company’s stock worth $603,000 after acquiring an additional 180 shares during the last quarter. Augustine Asset Management Inc. lifted its holdings in Dr. Reddy’s Laboratories by 0.4% during the 2nd quarter. Augustine Asset Management Inc. now owns 50,624 shares of the company’s stock worth $3,857,000 after purchasing an additional 181 shares during the last quarter. Lester Murray Antman dba SimplyRich lifted its holdings in Dr. Reddy’s Laboratories by 3.1% during the 2nd quarter. Lester Murray Antman dba SimplyRich now owns 6,178 shares of the company’s stock worth $470,000 after purchasing an additional 184 shares during the last quarter. Sequoia Financial Advisors LLC boosted its stake in Dr. Reddy’s Laboratories by 1.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 14,526 shares of the company’s stock valued at $1,065,000 after purchasing an additional 232 shares during the period. Finally, First Trust Direct Indexing L.P. boosted its stake in Dr. Reddy’s Laboratories by 2.4% in the 1st quarter. First Trust Direct Indexing L.P. now owns 10,634 shares of the company’s stock valued at $780,000 after purchasing an additional 251 shares during the period. Institutional investors own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE RDY opened at $79.20 on Friday. The business has a fifty day moving average price of $80.77 and a two-hundred day moving average price of $75.53. The stock has a market capitalization of $13.22 billion, a PE ratio of 19.65, a P/E/G ratio of 1.84 and a beta of 0.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.55 and a quick ratio of 1.90. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $63.72 and a fifty-two week high of $84.46.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Saturday, July 27th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.10). Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%. The company had revenue of $919.80 million during the quarter, compared to analyst estimates of $861.68 million. As a group, equities analysts predict that Dr. Reddy’s Laboratories Limited will post 4.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RDY. Barclays boosted their target price on shares of Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 16th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.